Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
9
Job creation lowest on record among under-30s
-
10
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
Medytox says China approvals proceeding without glitch
By Lim Jeong-yeoPublished : June 5, 2019 - 17:31
Government approval for wrinkle-smoothening botulinum toxin Medytoxin is proceeding as planned in China under the name Neuronox, Korean BTX maker Medytox said Wednesday in a regulatory filing.
It came in response to a local media report that claimed the China Food and Drug Administration has ceased its review of Neuronox.
It came in response to a local media report that claimed the China Food and Drug Administration has ceased its review of Neuronox.
On Wednesday, shares of Medytox shares closed at 435,000 won ($370), down 7.76 percent from a day earlier.
Medytox said the Neuronox is in the final stage of the approval process, and it has not been notified of any cessation of review.
Medytox had applied for sales approval of Neuronox in China in February 2018.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
